XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 17, 2022
Jun. 30, 2021
May 11, 2021
Apr. 09, 2021
Jan. 06, 2021
Aug. 12, 2020
Aug. 01, 2020
Jul. 15, 2020
Jul. 14, 2020
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Stock option vested exercisable term                             15 months  
Stock based compensation                         $ 424,094 $ 850,804 $ 763,766 $ 1,506,836
Number of fully vested option exercisable 2,225,000                   2,225,000   2,225,000   2,225,000  
Total deferred compensation expense for outstanding value of unvested stock options                             $ 1,808,000  
Fair market value, per share                             $ 0.74  
Outstanding stock options to acquire shares of common stock not vested 1,100,000                   1,100,000   1,100,000   1,100,000  
Director [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Stock option vested exercisable term           5 years                    
Stock options are exercisable price per share           $ 3.21                    
Fair value of stock options           $ 571,312                    
Stock price per share           $ 2.8566                    
Number of fully vested option issued           200,000                    
Non Officer Directors [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Stock options description the Board of Directors, in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, granted to each of the five non-officer directors of the Company stock options exercisable for a period of five years to purchase 100,000 shares (a total of 500,000 shares) of the Company’s common stock at an exercise price of $0.74 per share (the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested. The total fair value of the 500,000 stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $316,700 ($0.6334 per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2023. During the three months and six months ended June 30, 2022, the Company did not record a charge to operations with respect to these stock options   the Board of Directors, in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, granted to each of the five non-officer directors of the Company stock options exercisable for a period of five years to purchase 100,000 shares (a total of 500,000 shares) of the Company’s common stock at an exercise price of $3.03 per share (the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested. The total fair value of the 500,000 stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $1,421,095 ($2.84225 per share), which is being charged to operations ratably from July 1, 2021 through June 30, 2023. During the three months and six months ended June 30, 2022, the Company recorded a charge to general and administrative costs in the consolidated statement of operations of $177,150 and $352,355, respectively, with respect to these stock options                          
Stock option vested exercisable term     5 years                          
Stock options are exercisable price per share $ 0.74   $ 3.03               $ 0.74 $ 3.03 $ 0.74 $ 3.03 $ 0.74 $ 3.03
Fair value of stock options                     $ 316,700 $ 1,421,095        
Stock price per share $ 0.6334   $ 2.84225               $ 0.6334 $ 2.84225 $ 0.6334 $ 2.84225 $ 0.6334 $ 2.84225
Stock based compensation                         $ 177,150   $ 352,355  
Number of fully vested option exercisable 500,000   500,000               500,000 500,000 500,000 500,000 500,000 500,000
Stock options granted to purchase common stock, issued                     500,000 500,000        
Five Non Officer Directors [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Number of fully vested option exercisable 100,000   100,000               100,000 100,000 100,000 100,000 100,000 100,000
BasvanderBaan [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Stock options description   the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Mr. Baan was granted options exercisable for a period of five years to purchase 250,000 shares of the Company’s common stock at an exercise price of $0.74 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $158,525 ($0.6341 per share), of which $79,263 was attributable to the stock options fully-vested on June 17, 2022 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from June 17, 2022 through June 30, 2024. During the three months and six months ended June 30, 2022, the Company recorded a charge to general and administrative costs in the consolidated statement of operations of $80,647 with respect to these stock options                            
Stock option vested exercisable term   5 years                            
Stock options are exercisable price per share   $ 0.74                            
Fair value of stock options   $ 158,525                            
Stock price per share   $ 0.6341                            
Stock based compensation                         $ 80,647   $ 80,647  
Number of fully vested option exercisable   250,000                            
Stock options granted to purchase common stock, issued   79,263                            
DrWinson SzeChunHo [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Number of fully vested option issued           50,000                    
DrYunYen [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Number of fully vested option issued           50,000                    
DrStephenForman [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Number of fully vested option issued           50,000                    
Philip Palmedo [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Number of fully vested option issued           50,000                    
Eric J. Forman [Member] | Employment Agreement [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Stock options description                 On July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman was granted options for 58,333 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options have a term of five years and an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vested as to 25% on August 12, 2020 and August 12, 2021, and will vest 25% on each of the second and third anniversaries of the grant date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $400,855 ($6.8718 per share), of which $100,214 was attributable to the stock options fully-vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the three months ended June 30, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $24,985 and $24,985, respectively, with respect to these stock options. During the six months ended June 30, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $49,695 and $49,695, respectively, with respect to these stock options              
Stock options granted to purchase common stock, issued                 58,333              
Stock option vested exercisable term                 5 years              
Stock options are exercisable price per share                 $ 7.14              
Fair value of stock options                 $ 400,855              
Stock price per share                 $ 6.8718              
Stock options fully vested amount, fair value             $ 100,214                  
Stock based compensation                         24,985 $ 24,985 49,695 $ 49,695
Dr. James Miser [Member] | Employment Agreement [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Stock options description               Dr. James S. Miser, M.D., Dr. Miser was granted options for 83,334 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options have a term of five years and an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the effective date of the employment agreement. The options vested as to 25% on August 1, 2020 and August 1, 2021, and will vest 25% on each of the second and third anniversaries of the effective date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $572,650 ($6.8718 per share), of which $143,163 was attributable to the stock options fully-vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 1, 2020 through August 1, 2023. During the three months ended June 30, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $35,693 and $35,693, respectively, with respect to these stock options. During the six months ended June 30, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $70,993 and $70,993, respectively, with respect to these stock options                
Stock options granted to purchase common stock, issued               83,334                
Stock options are exercisable price per share               $ 7.14                
Fair value of stock options               $ 572,650                
Stock price per share               $ 6.8718                
Stock options fully vested amount, fair value               $ 143,163                
Stock based compensation                         35,693 35,693 70,993 70,993
Robert N. Weingarten [Member] | Employment Agreement [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Stock options description             On August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted options for 58,333 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options have a term of five years and an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vested as to 25% on August 12, 2020 and August 12, 2021, and will vest 25% on each of the second and third anniversaries of the grant date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $400,855 ($6.8718 per share), of which $100,214 was attributable to the stock options fully-vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the three months ended June 30, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $24,985 and $24,985, respectively, with respect to these stock options. During the six months ended June 30, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $49,695 and $49,695, respectively, with respect to these stock options                  
Stock options granted to purchase common stock, issued             58,333                  
Stock option vested exercisable term             5 years                  
Stock options are exercisable price per share             $ 7.14                  
Fair value of stock options             $ 400,855                  
Stock price per share             $ 6.8718                  
Stock options fully vested amount, fair value             $ 100,214                  
Stock based compensation                         24,985 24,985 49,695 49,695
DrWinson SzeChunHo [Member] | Director [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Stock options description         Winson Sze Chun Ho resigned from the Company’s Board of Directors to focus on clinical and pre-clinical cancer research in academic medicine. Concurrent with his resignation, the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by Dr. Ho’s resignation. In connection with his appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Mr. Schwartzberg was granted options exercisable for a period of five years to purchase 250,000 shares of the Company’s common stock at an exercise price of $3.20 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $753,611 ($3.0144 per share), of which $376,800 was attributable to the stock options fully-vested on April 9, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from April 9, 2021 through June 30, 2023. During the three months ended June 30, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $42,228 and $414,851, respectively, with respect to these stock options. During the six months ended June 30, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $83,992 and $414,851, respectively, with respect to these stock options                      
Stock option vested exercisable term         5 years                      
Stock options are exercisable price per share         $ 3.20                      
Fair value of stock options         $ 753,611                      
Stock price per share         $ 3.0144                      
Stock options fully vested amount, fair value         $ 376,800                      
Stock based compensation                         42,228 414,851 83,992 414,851
Number of fully vested option exercisable         250,000                      
Ms.Regina Brown [Member] | Director [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Stock options description       the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Ms. Brown was granted options exercisable for a period of five years to purchase 250,000 shares of the Company’s common stock at an exercise price of $2.80 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $658,363 ($2.6335 per share), of which $329,188 was attributable to the stock options fully-vested on May 11, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from May 11, 2021 through June 30, 2023. During the three months ended June 30, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $38,405 and $350,290, respectively, with respect to these stock options. During the six months ended June 30, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $76,388 and $350,290, respectively, with respect to these stock options                        
Stock option vested exercisable term       5 years                        
Stock options are exercisable price per share       $ 2.80                        
Fair value of stock options       $ 658,363                        
Stock price per share       $ 2.6335                        
Stock options fully vested amount, fair value       $ 329,188                        
Stock based compensation                         $ 38,405 $ 350,290 $ 76,388 $ 350,290
Number of fully vested option exercisable       250,000                        
2020 Stock Incentive Plan [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Shares issued 2,100,000                   2,100,000   2,100,000   2,100,000  
Shares outstanding 2,100,000                   2,100,000   2,100,000   2,100,000  
Shares were available for issuance 233,333                   233,333   233,333   233,333  
2020 Stock Incentive Plan [Member] | Maximum [Member]                                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                
Number of restricted stock issued                   2,333,333